Ventilator associated pneumonia caused by extensive-drug resistant Acinetobacter species: Colistin is the remaining choice

Peer review under responsibility of Egyptian Society of Anesthesiologists.

Figures & data

able 1 Demographic data. Data are described as mean ± SD, median (quartiles).

	AB-VAP patients (n = 30)	Non-AB-VAP patients (17)	P value
Age (years)	39 ± 22	43 ± 20	0.5
Gender (male/female)	19/11	12/5	0.7
APACHE II	18(15–22)	17(15–22)	0.8
SOFA on admission	6(3–8)	5(2–8)	0.5

able 2 Risk factors for acquisition of VAP. Data are presented as mean ± standard deviation and number (frequency).

	AB-VAP patients (n = 30)	Non-AB-VAP patients (n = 17)	P value
Diabetes	6(20%)	5(29.4%)	0.4
Blood transfusion {number of patients (%)}	10(33.3%)	5(29.4%)	0.7
Sepsis	7(23.3%)	7(41.2%)	0.2
Serum Albumin (gm/dl)	2.5(2.2–3.1)	2.3(2.3–2.6)	0.6
Previous antimicrobial therapy	12(40.0%)	8(47.1%)	0.63
Previous mechanical ventilation	6(20.7%)	5(29.4%)	0.5
Duration of ventilation before infection	6 ± 4	4 ± 4	0.1
TPN	3(10%)	1(5.9%)	0.3
H2 blockers	26(86.7%)	15(88.2%)	0.87
Proton pump inhibitors	4(13.3%)	3(17.6%)	1.0
Steroids	15(50%)	7(41%)	0.6
Patients with previously inserted central line	27(90%)	13(76.5%)	0.3
Previous surgery	11(36.7%)	9(52.9%)	0.27
Patients with history of repeated operation	7(23.3%)	4(23.5%)	0.9
Hemodialysis	6(20%)	1(5.9%)	0.24

able 3 Multivariate analysis factor predicting AB-VAP.

		Odds ratio	95% CI	P value
APACHE II	<20	1	(0.2–4)	0.09
	>20	1.08	(0.2–4)	0.09
Dialysis	Yes	1	(0.6–3.7)	0.4
	No	0.8	(0.6–3.7)	0.4
Diabetes	Yes	1	(0.4–12)	0.4
	No	2.1	(0.4–12)	0.4
Transfusion	Yes	1	(0.2–5)	0.9
	No	0.9	(0.2–5)	0.9
TPN	Yes	1	(0.8–14)	0.9
	No	1.5	(0.8–14)	0.9
Reoperation	Yes	1	(0.75–5)	0.76
	No	1.2	(0.75–5)	0.76

able 4 Patients outcome. Data are presented as median (IQR), and number (frequency).

	AB-VAP patients (n = 30)	Non-AB-VAP patients (n = 17)	P value
Ventilation days	7(6–11)	11(7–16)	0.2
Length of ICU stay	15(11–34)	20(15–40)	0.2
Mortality	16(53.3%)	9(52.9%)	0.75